The deal priced below last closing price of $11.21. H.C. Wainwright is acting as sole book running manager for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
- Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial
- Gyre Therapeutics announces Hydronidone trial met primary endpoint
- Gyre Therapeutics announces common stock offering, no amount given
- Gyre Therapeutics Reports Q1 2025 Financial Results